Pascal Deschatelets News Today

Frazier Life Sciences Management L.P. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 44.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 885,165 shares of the company’s stock after acquiring an additional 271,122 shares during the […]

KPP Advisory Services LLC boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 17.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,196 shares of the company’s stock after purchasing an additional 1,675 shares during the quarter. KPP Advisory Services LLC’s […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $92.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 123.79% from the company’s previous close. […]

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts also recently issued reports about the stock. Wedbush dropped their price objective […]

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also recently issued research reports about the stock. […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 3.5% during trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $48.01 and last traded at $48.11. 88,800 shares changed hands during trading, […]

HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $92.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. UBS Group upped their target price on Apellis […]

Xponance Inc. reduced its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 6.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,927 shares of the company’s stock after selling 939 shares during the quarter. Xponance Inc.’s holdings in Apellis Pharmaceuticals […]

Jennison Associates LLC reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, Holdings Channel reports. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC’s holdings in Apellis Pharmaceuticals were worth $196,097,000 at the end of […]

Jennison Associates LLC lessened its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC owned 2.76% of Apellis Pharmaceuticals […]